Aprea Therapeutics, Inc.

NasdaqCM:APRE Stok Raporu

Piyasa değeri: US$21.3m

Aprea Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Aprea Therapeutics has a total shareholder equity of $26.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $30.0M and $3.1M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$28.69m
EşitlikUS$26.87m
Toplam yükümlülüklerUS$3.09m
Toplam varlıklarUS$29.96m

Son finansal sağlık güncellemeleri

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

Aug 06
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Jan 10
We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Recent updates

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

Aug 06
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Jan 10
We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: APRE's short term assets ($29.6M) exceed its short term liabilities ($3.1M).

Uzun Vadeli Yükümlülükler: APRE has no long term liabilities.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: APRE is debt free.

Borcun Azaltılması: APRE had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: APRE has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: APRE has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 41.4% each year.


Sağlıklı şirketleri keşfedin